SS-31 25mg
Mid-Size SS-31 for Extended Mitochondrial and Cardiac Research
The 25mg SS-31 vial enables comprehensive multi-week mitochondrial protection and cardiac research protocols at superior per-mg value to the entry 10mg.
Mid-Size SS-31 for Extended Mitochondrial and Cardiac Research
Same elamipretide cardiolipin-targeting tetrapeptide at 2.5x the quantity for extended mitochondrial biology and cardiac protection studies.
As one of the most studied compounds in the recovery & healing research space, SS-31 has attracted sustained scientific interest across Extended mitochondrial research, Multi-week cardiac studies. Peer-reviewed evidence indicates that 25mg supports extended cardiac research, which has positioned SS-31 as a reference standard for researchers exploring extended mitochondrial research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
SS-31 Documented Benefits: 1 Documented Mechanisms
Extended Protocol Supply
Supports multi-week cardiac and mitochondrial research without restocking.
How SS-31 Works: Molecular Mechanism & Pathway
Same SS-31 cardiolipin-binding inner mitochondrial membrane stabilization mechanism.
The 1 primary research pathways identified for SS-31 — Extended Protocol Supply — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that mid-range value option, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, SS-31's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
SS-31 is routinely studied alongside MOTS-c and SS-31 in recovery & healing-focused compound panels. Researchers investigating extended mitochondrial research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that same clinical-grade purity has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All SS-31 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 25mg supports extended cardiac research
- Mid-range value option
- Same clinical-grade purity
Ideal For
- Extended mitochondrial research
- Multi-week cardiac studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on SS-31. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
25mg supports extended cardiac research
Mid-range value option
Same clinical-grade purity
Third-Party Verified Every Batch
Each vial of SS-31 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
